Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06890923 · ClinicalTrials.gov registry record · Phase 2
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
A Phase 2 study of Non-Active Secondary Progressive Multiple Sclerosis, sponsored by Tiziana Life Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT06890923 is a Phase 2 study of Non-Active Secondary Progressive Multiple Sclerosis that is actively recruiting participants, run by Tiziana Life Sciences. The registered enrollment target is 55 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06890923, a Phase 2 study of Non-Active Secondary Progressive Multiple Sclerosis, is actively recruiting participants, sponsored by Tiziana Life Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
Only subjects that have completed TILS-021, a Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients are eligible to be enrolled in TILS-022. TILS-022 is a 6-month open-label extension study with an opportunity for dose to be escalated based on the subject's clinical status. All subjects initiate dosing in this trial at a dose of nasal foralumab 50 µg 3 days a week (Monday, Wednesday, and Friday) for 2 weeks, followed by a 1-week rest, comprising a 3-week cycle. At week 12, the dose may be escalated to 100 µg according to pre-defined dose escalation rules. Study TILS-022 is intended to ensure all participants in TILS-021, a placebo-controlled study, will be able to receive open-label nasal foralumab for 6 months. The option to extend this trial for longer than 6 months will be explored with FDA by the Sponsor.
Conditions Studied
Interventions
- DRUG Foralumab TZLS-401 100 µg
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2025-03-04 |
| Est. Completion | 2026-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06890923
The ClinicalTrials.gov registry entry for NCT06890923 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tiziana Life Sciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Active Secondary Progressive Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Foralumab TZLS-401 100 µg is the first listed.
NCT06890923 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06890923 about?
NCT06890923 is a clinical study titled "Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis". Only subjects that have completed TILS-021, a Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients are eligible to be enrolled in TILS-022. TILS-022 is a 6-month open-label extension s...
What is the current status of trial NCT06890923?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2025-03-04. Estimated completion is 2026-08-30.
What conditions does trial NCT06890923 study?
This clinical trial studies the following conditions: Non-Active Secondary Progressive Multiple Sclerosis.
What interventions are being tested in trial NCT06890923?
The interventions under investigation include: Foralumab TZLS-401 100 µg (DRUG).
Who is sponsoring clinical trial NCT06890923?
This trial is sponsored by Tiziana Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06890923 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.